CHIESI FARMACEUTICI R&D II

The project consists of Chiesi’s research and development activities in Italy and partly (8%) in the UK, oriented towards (i) respiratory diseases, (ii) specific technology platform (nebulised and pulverised dosage forms) and (iii) infant respiratory distress syndrome (IRDS) or neonatal respiratory distress syndrome (NRDS).

Improving the health of European citizens and increasing the competitiveness and boosting the innovative capacity of European health-related industries and businesses, while addressing global health issues including emerging epidemics, is one of the key objectives of the FP-7 on research. This research focuses, inter alia, on respiratory diseases including those induced by allergies, as they have a high impact on the quality of life.

R&D activities included in the project will not materially change current R&D practice and will be carried out within existing facilities, making use of existing laboratories, pilot plants, clinical centres, etc. An Environmental Impact Assessment (EIA), therefore, is not required by EU Directive 97/11 amended by Directive 2003/35.

The promoter is a private company, not operating in the Utilities sector and therefore not covered by EU Directives on procurement. Procedures followed are in the best interest of the project and satisfactory to the Bank.